Analysts expect Alnylam Pharmaceuticals, Inc. to report revenue of 1.48 B for Q3 26, against a range of 1.34 B to 1.62 B. The most recent reported quarter, Q2 26, came in at 1.29 B, a 6.8% miss against the 1.38 B consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 500.92 M | 593.17 M | 594.19 M | 773.69 M | 1.25 B | 1.10 B | 1.17 B | 1.29 B | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 619.41 M | 593.45 M | 575.46 M | 709.49 M | 1.11 B | 1.23 B | 1.23 B | 1.47 B | 1.62 B | 1.77 B | 1.63 B | 1.79 B | 2.21 B | 2.44 B | 1.96 B | 1.82 B | ||||||||||
| Low Estimate | 511.47 M | 500.18 M | 535.64 M | 651.62 M | 914.97 M | 1.15 B | 1.14 B | 1.30 B | 1.34 B | 1.54 B | 1.40 B | 1.52 B | 2.03 B | 2.17 B | 1.67 B | 1.62 B | ||||||||||
| Consensus Estimate | 565.44 M | 546.82 M | 555.55 M | 680.56 M | 1.01 B | 1.19 B | 1.18 B | 1.38 B | 1.48 B | 1.66 B | 1.52 B | 1.65 B | 2.12 B | 2.30 B | 1.82 B | 1.72 B |
Analysts expect Alnylam Pharmaceuticals, Inc. to report earnings per share of 1.68 for Q3 26, against a range of 1.63 to 1.73. The most recent reported quarter, Q2 26, came in at 1.21, a 28.0% miss against the 1.68 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.87 | -0.65 | -0.44 | -0.51 | 1.84 | 0.82 | 1.51 | 1.21 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.89 | -0.59 | -0.85 | -0.47 | 0.58 | 1.28 | 0.92 | 1.77 | 1.73 | 2.40 | 2.16 | 2.70 | 3.29 | 3.35 | 2.56 | 3.00 | ||||||||||
| Low Estimate | -1.03 | -0.65 | -1.03 | -0.57 | 0.48 | 1.14 | 0.76 | 1.59 | 1.63 | 2.00 | 1.98 | 2.32 | 2.73 | 3.15 | 2.38 | 2.62 | ||||||||||
| Consensus Estimate | -0.96 | -0.62 | -0.94 | -0.52 | 0.53 | 1.21 | 0.84 | 1.68 | 1.68 | 2.20 | 2.07 | 2.51 | 3.01 | 3.25 | 2.47 | 2.81 |
Pull Wall Street consensus for Alnylam Pharmaceuticals, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=ALNY&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "ALNY", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=ALNY&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();